An international team of clinical collaborators, led by physician scientists from Dana-Farber/Boston Children's Cancer and ...

An international team of clinical collaborators, led by physician scientists from Dana-Farber Cancer Institute, performed a ...

An international team of clinical collaborators, led by physician scientists from Dana-Farber Cancer Institute, performed a first-ever clinical test of the targeted therapy avapritinib in pediatric ...

High-grade glioma, a difficult-to-treat and aggressive form of pediatric and adult brain cancer, responded to FDA-approved avapritinib. | Drug Discovery And Development ...

一项发表在《Cancer Cell》杂志上的研究显示，携带基因PDGFRA DNA改变的高级别胶质瘤肿瘤细胞对药物avapritinib有反应。阿伐替尼，商品名为泰吉华® (AYVAKIT®), 是一款高特异性KIT和PDGFRA激酶抑制剂。该药物已获得美国食品药品监督管理局批准用于治疗携带PDGFRA外显子18突变的胃肠间质瘤以及晚期系统性肥大细胞增多症和惰性系统性肥大细胞增多症。

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

发表在《癌细胞》（Cancer Cell）杂志上的一项研究表明，含有PDGFRA基因DNA改变的高级胶质瘤细胞对药物avapritinib有反应，avapritinib已被美国食品和药物管理局（fda）批准用于治疗PDGFRA外显子18突变的胃肠道间质肿瘤以及晚期系统性肥大细胞增多症和惰性系统性肥大细胞增多症。

A study shows that high-grade glioma tumor cells harboring DNA alterations in the gene PDGFRA responded to the drug avapritinib, which is already approved by the United States Food and Drug ...

文章中说，血小板源性生长因子受体α（PDGFRA）对肿瘤的发生至关重要，在高级别胶质瘤（HGG）中经常发生基因组改变。在包含 261 例儿童高级别胶质瘤的综合数据集中，研究者检测到 15% 的病例存在 PDGFRA 突变和/或扩增，这表明 ...

A new therapy offers hope for treating pediatric brain tumors, targeting cancer cells while minimizing side effects for young ...